Introduction
Pharmaceutical products form an important component of healthcare in developing and developed countries. Innovative pharmaceuticals enable new treatments and prevention of diseases. While pharmaceuticals represent only one among many health inputs, new drugs may provide an alternative to non-drug inputs such as invasive operations (Schweitzer 2007) . Reflecting their importance, expenditures on pharmaceuticals take up a substantial percentage of total spending on healthcare. In 2000, this ratio was 19.2 per cent in low-income countries taken as a whole. This is even higher than the corresponding figure of 13.8 per cent for high-income countries (WHO 2004: 42) . In the same year, per capita expenditure on pharmaceuticals was estimated to be only US$4.40 per year in low-income countries while it was US$396 per year in highincome countries (WHO 2004: 45) . 1 Thus, there appears to be a huge disparity in the role of pharmaceuticals between rich and poor countries.
The low level of drug spending in developing countries reflects a severe lack of access. The World Health Organization (WHO) estimates that between 1.3 and 2.2 billion people (from 22 per cent to 37 per cent of the world's population) lacked access to essential medicines in 1999 (WHO 2004: 62) . A series of surveys sponsored by the WHO and Health Action International shows that essential medicines are available in only 34.9 per cent of public-sector health facilities in developing countries (United Nations 2008). The proportion of private-sector health facilities having a stock of essential medicines is somewhat higher (63.2 per cent). The lack of access to medicines has serious implications for healthcare in developing countries; regions with less access have significantly lower levels of disability-adjusted life expectancy (WHO 2004) .
A major impediment to accessing pharmaceuticals in developing countries is the lack of a healthcare system and infrastructure in which drugs can be distributed and used properly. There is a general shortage of trained doctors and other health professionals who can properly prescribe appropriate medications (Commission on Macroeconomics and Health 2001: 86) . Further, the absence of universal health insurance coverage in most developing countries means that a large part of drug consumption must be met 'out-of-pocket' by individuals, many of whom live in poverty. Even if the government rather than the individual paid for pharmaceuticals, many developing countries would still be incapable of financing the full pharmaceutical needs of their citizens (Commission on Macroeconomics and Health 2001: 86) .
The issue of access is further complicated for patented drugs. A patent gives the patent holder the exclusive right to manufacture and sell the drug for a certain period. There are many circumstances in which patents and other intellectual property rights can affect access to pharmaceuticals. First, if patents exist for the medicines needed in developing countries, and the patent holder does not supply to these countries, the medicines will be inaccessible to patients. Second, the patent system allows new pharmaceuticals to be sold at prices that are higher than competitive levels. High prices for patented drugs are often justified by the patent-holder's need to recover the cost of research and development (R&D), including the clinical studies to ensure the safety and efficacy of the medicines. Such prices are affordable for patients in developed countries who are covered by health insurance but may not be so for a large number of people in developing countries. For the vast majority of essential medicines as defined by the WHO, however, these issues do not arise because very few such medicines remain under patent.
2 Nevertheless, some diseases require the use of new and patented drugs for basic treatment.
Lack of access to essential drugs has been particularly severe for acquired immunodeficiency syndrome (AIDS) patients infected by the human immunodeficiency virus (HIV). As recently as 2003, only 7 per cent of those needing treatment for AIDS in low and middleincome countries were actually receiving treatment (WHO 2006a: 19) . The scourge of AIDS has been devastating, particularly in sub-Saharan Africa. It is estimated that between 1.5 and 2 million people died from the disease in sub-Saharan Africa in 2007, and more than 20 million people continue to live with the virus (UNAIDS 2007).
